BUZZ - Myriad's stock surges after agreeing to sell its prenatal health testing business

October 20 - ** The genetic testing company Myriad Genetics (MYGN.O) saw its shares rise by 20.7% in pre-market trading, reaching $5.05

** The company announced it will sell its prenatal health testing business to Labcorp (LH.N) for $210 million in cash plus inventory value

** MYGN stated that the transaction is expected to drive revenue growth and profitability for Myriad, while also strengthening its balance sheet

** Labcorp expects the deal to generate approximately $160 million in revenue in the first year

** Myriad's prenatal testing portfolio includes multiple genetic screening products designed for pregnancy and reproductive health

** As of the last close, MYGN shares were down 31% year-to-date

(To facilitate non-English speakers, Reuters has made its reports available in several other languages through automated translation. As automated translation may contain errors or fail to capture the required context, Reuters does not guarantee the accuracy of the automated translation text, which is provided solely for your convenience. Reuters accepts no liability for any damage or loss caused by the use of automated translation.)